Effect of CpG ODN on monocytic myeloid derived suppressor cells

OncoImmunology

Volumn 1, Issue 5, 2012, Pages 780-782

  Shirota, Hidekazu ^a,b   Klinman, Dennis M ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b SAIC FREDERICK INC   (United States)

Author keywords

CpG ODN; CpG oligonucleotides; Immunotherapy; Myeloid derived suppressor cells; Myeloid derived suppressor cells; TLR9; Toll like receptor; Tumor microenvironment; Tumor associated macrophages

Indexed keywords

INTERLEUKIN 12; OLIGONUCLEOTIDE; TOLL LIKE RECEPTOR 9;

ARTICLE; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CD8+ T LYMPHOCYTE; CPG ISLAND; LYMPHOCYTE ACTIVATION; LYMPHOCYTE PROLIFERATION; MACROPHAGE; MONOCYTE; NATURAL KILLER CELL; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; SKIN CANCER; SUPPRESSOR CELL; TUMOR IMMUNITY; TUMOR REGRESSION;

EID: 84877600956     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.19731     Document Type: Article

References (11)

1. Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol 2010; 11:373-84; PMID: 20404851; http://dx.doi.org/10.1038/ni.1863
2. Klinman DM. Immunotherapeutic uses of CpG oligodeoxynucleotides. Nat Rev Immunol 2004; 4:249-58; PMID:15057783; http://dx.doi.org/10.1038/nri1329
3. Heckelsmiller K, Rall K, Beck S, Schlamp A, Seiderer J, Jahrsdörfer B, et al. Peritumoral CpG DNA elicits a coordinated response of CD8 T cells and innate effectors to cure established tumors in a murine colon carcinoma model. J Immunol 2002; 169:3892-9; PMID:12244187
4. Vollmer J, Krieg AM. Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists. Adv Drug Deliv Rev 2009; 61:195-204; PMID:19211030; http://dx.doi.org/10.1016/j.addr.2008.12.008
5. Zitvogel L, Tesniere A, Kroemer G. Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol 2006; 6:715-27; PMID: 16977338; http://dx.doi.org/10.1038/nri1936
6. Ostrand-Rosenberg S, Sinha P. Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol 2009; 182:4499-506; PMID:19342621; http://dx.doi.org/10.4049/jimmunol.0802740
7. Shirota Y, Shirota H, Klinman DM. Intratumoral injection of CpG oligonucleotides induces the differentiation and reduces the immunosuppressive activity of myeloid-derived suppressor cells. J Immunol 2012; 188:1592-9; PMID:22231700; http://dx.doi.org/10.4049/jimmunol.1101304
8. Biswas SK, Mantovani A. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol 2010; 11:889-96; PMID: 20856220; http://dx.doi.org/10.1038/ni.1937
9. Hofmann MA, Kors C, Audring H, Walden P, Sterry W, Trefzer U. Phase 1 evaluation of intralesionally injected TLR9-agonist PF-3512676 in patients with basal cell carcinoma or metastatic melanoma. J Immunother 2008; 31:520-7; PMID:18463532; http://dx.doi.org/10.1097/CJI.0b013e318174a4df
10. Brody JD, Ai WZ, Czerwinski DK, Torchia JA, Levy M, Advani RH, et al. In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study. J Clin Oncol 2010; 28:4324-32; PMID: 20697067; http://dx.doi.org/10.1200/JCO.2010.28.9793
11. + T-cell reactivity in melanoma patients. Clin Cancer Res 2008; 14:4532-42; PMID: 18628468; http://dx.doi.org/10.1158/1078-0432.CCR-07-4711